Infarct size measured by single photon emission computed tomographic imaging with 99mTc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction

Circulation

Volumn 101, Issue 1, 2000, Pages 101-108

  Gibbons, Raymond J ^a   Miller, Todd D ^a   Christian, Timothy F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Infarction; Radioisotopes; Tomography

Indexed keywords

ADENOSINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MYOSIN ANTIBODY IN 111; POLOXAMER; PYROPHOSPHATE TECHNETIUM TC 99M; STREPTOKINASE; THALLIUM 201; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0034602838     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.1.101     Document Type: Review

References (45)

1. Kennedy JW, Martin JC, David KB, Maynard C, Stadius M, Sheehan RH, Ritchie JL. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction randomized trial. Circulation. 1988;77:345-352.
2. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO, Zaret B. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI phase I) trial. Circulation. 1987;75:817-829.
3. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A, for the RAPID Investigators. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995;91:2725-2732.
4. Anglo-Scandinavian Study of Early Thrombolysis Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
5. DeCoster PM, Wijns W, Cauwe F, Robert A, Beckers C, Melin JA. Area-at-risk determination by technetium-99m-hexakis-2-methoxyisobutyl isonitrile in experimental reperfused myocardial infarction. Circulation. 1990;82:2152-2162.
6. Sinusas AJ, Trautman KA, Bergin JD, Watson DD, Ruiz M, Smith WH, Beller GA. Quantification of "area at risk" during coronary occlusion and degree of myocardial salvage after reperfusion with technetium-99m-methoxy isobutyl isonitrile. Circulation. 1990;82:1424-1437.
7. Gibbons RJ, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention. J Am Coll Cardiol. 1994;24:616-623.
8. Gibbons RJ, Verani MS, Behrenbeck T, Pellikka PA, O'Connor MK, Mahmarian JJ, Chesebro JH, Wackers FJ. Feasibility of tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of acute treatment in myocardial infarction. Circulation. 1989;80:1277-1286.
9. Christian TF, Behrenbeck T, Pellikka PA, Huber KC, Chesebro JH, Gibbons RJ. Mismatch of left ventricular function and perfusion with Tc-99 m-isonitrile following reperfusion therapy for acute myocardial infractions: identification of myocardial stunning and hyperkinesia. J Am Coll Cardiol. 1990;16:1632-1638.
10. Christian TF, Behrenbeck T, Gersh BJ, Gibbons RJ. Relation of left ventricular volume and function over one year after acute myocardial infarction to infarct size determined by technetium-99m sestamibi. Am J Cardiol. 1991;68:21-26.
11. Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger JA. The relationship of infarct size with the extent of left ventricular remodeling following myocardial infarction. J Am Coll Cardiol. 1995; 25:567-573.
12. Behrenbeck T, Pellikka PA, Huber KC, Bresnahan JF, Gersh BJ, Gibbons RJ. Primary angioplasty in myocardial infarction: assessment of improved myocardial perfusion with technetium-99m-isonitrile. J Am Coll Cardiol. 1991;17:365-372.
13. Christian TF, O'Connor MK, Hopfenspirger MR, Gibbons RJ. Comparison of reinjection thallium 201 and resting technetium 99m sestamibi tomographic images for the quantification of infarct size after acute myocardial infarction. J Nucl Cardiol. 1994;1:17-28.
14. 99mTc sestamibi in patients undergoing cardiac transplantation. Circulation. 1996;94:1010-1017.
15. Maes AF, Borgers M, Flameng W, Nuyts JL, Van de Werf F, Ausma JJ, Sergeant P, Mortelmans LA. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. J Am Coll Cardiol. 1997;29:62-68.
16. 99mTc-sestamibi tomography before coronary bypass graft surgery: correlation with histopathology and postoperative improvement in cardiac function. Circulation. 1997;96: 2892-2898.
17. Ideker RE, Behar VS, Wagner GS, Starr JW, Starmer F, Lee KL, Hackel DB. Evaluation of asynergy as an indicator of myocardial fibrosis. Circulation. 1978;57:715-725.
18. Sinusas AJ, Hardin NJ, Clements JP, Wackers FJ. Pathoanatomic correlates of regional left ventricular wall motion assessed by equilibrium radionuclide angiocardiography: a postmortem correlation. Am J Cardiol. 1984;54:975-981.
19. Cabin HS, Clubb KS, Vita N, Zaret BL. Regional dysfunction by equilibrium radionuclide angiocardiography: a clinicopathologic study evaluating the relation of degree of dysfunction to the presence and extent of myocardial infarction. J Am Coll Cardiol. 1987;10:743-747.
20. Shen WK, Khandheria BK, Edwards WD, Oh JK, Miller FA, Naessens JM, Tajik AJ. Value and limitations of two-dimensional echocardiography in predicting myocardial infarct size. Am J Cardiol. 1991;68: 1143-1149.
21. 99mTc-sestamibi. Circulation. 1994;89:2552-2561.
22. 99mTc sestamibi imaging predicts subsequent mortality. Circulation. 1995;92:334-341.
23. O'Connor MK, Hammell T, Gibbons RJ. In vitro validation of a simple tomographic technique for estimation of percent myocardium "at risk" using technetium-99m methoxy isobutyl isonitrile (sestamibi). Eur J Nucl Med. 1990;17:69-76.
24. Miller TD, Hodge DO, Sutton JM, Grines CL, O'Keefe JH, DeWood MA, Okada RD, Fletcher WO, Gibbons RJ. Technetium-99m sestamibi infarct size predicts mortality. Am J Cardiol. 1998;81:1491-1493.
25. Burns RJ, Gibbons RJ, Roberts RS, Tadros SS, Miller TD, Foster G, Yusuf S. LV function and infarct size predict six-month mortality post MI treated by thrombolysis. Circulation. 1996;94(suppl I):I-655. Abstract.
26. Gibbons RJ, Holmes DR, Reeder GS, Bailey KK, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993;328:685-691.
27. Schaer GL, Spaccarento LJ, Bronne KF, Kraeger KA, Krichbaum D, Phelan JM, Frehher WO, Grines LL, Edwards S, Jolly MK, Gibbons RJ. Beneficial effects of RheothRX injection in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation. 1996; 94:298-307.
28. O'Keefe JH Jr, Grines CL, DeWood MA, Schaar GL, Browne K. Majorien RD, Kalbfleisch JM, Fletcher WO Jr, Bakman TM, Gibbons RJ. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 78:747-750.
29. Collaborative Organization for RheothRX Evaluation (CORE). Effects of RheothRX on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation. 1997;96: 192-201.
30. Garratt KN, Holmes DR, Molina-Viamonte V, Reeder GS, Hodge D, Bailey KR, Lobl J, Laudon D, Gibbons RJ. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J. 1998; 136:196-204.
31. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF Eisenberg PR, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB, for the AMISTAD Investigators. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. In press.
32. Christian TF, Gitter MJ, Miller TD, Gibbons RJ. Prospective identification of myocardial stunning using technetium-99m sestamibi-based measurements of infarct size. J Am Coll Cardiol. 1997;30:1633-1640.
33. Johnson LL, Lerrick KS. Coromilas J, Seldin DW, Esser PD, Zimmerman JM, Keller AM, Alderson PO, Bigger JT, Cannon PJ. Measurement of infarct size and percentage myocardium infarcted in a dog preparation with single photon-emission computed tomography, thallium-201. and indium 111 monoclonal antimyosin Fab. Circulation. 1987;76:181-190.
34. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. J Am Coll Cardiol. 1992;20:1452-1459.
35. O'Connor MK, Caiati C, Christian TF, Gibbons RJ. Effects of scatter correction on the measurement of infarct size from SPECT cardiac phantom studies. J Nucl Med. 1995;36:2080-2086.
36. Christian TF, O'Connor MK, Glynn RB, Rogers PJ, Gibbons RJ. The influence of gating on measurements of myocardium at risk and infarct size during acute myocardial infarction by tomographic technetium-99m sestamibi imaging. J Nucl Cardiol. 1995;2:207-216.
37. O'Connor MK, Gibbons RJ, Juny JE, O'Keefe JH Jr, Ali A. Quantitative myocardial SPECT for infarct sizing: feasibility of a multicenter trial evaluated using a cardiac phantom. J Nucl Med. 1995;36:1130-1136.
38. Galli M, Mariassa C, Bolli R, Grannuzzi P, Temporelli PL, Importo A, Silva Orrego PL, Giubbini R, Giordano A, Tavazzi L. Spontaneous delayed recovery of perfusion and contraction after the first five weeks after anterior infarction. Circulation. 1994;90:1386-1397.
39. Christian TF, Gibbons RJ, Gersh BJ. Effect of infarct location on myocardial salvage assessed by technetium-99m isonitrile. J Am Coll Cardiol. 1991;17:1303-1308.
40. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Eng J Med. 1993;328:673-679.
41. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997; 336:1621-1630.
42. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
43. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
44. Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT) trial to investigate equivalence. Lancet. 1995;346:329-336.
45. Transcript of proceedings. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Cardiovascular and Renal Drugs Advisory Committee. 67th meeting, December 16, 1992. Washington, DC: Miller Reporting Co Inc.